Trinka, E., Steinhoff, B.J., Nikanorova, M. and Brodie, M.J. (2016) Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurologica Scandinavica, 133(3), pp. 160-172. (doi: 10.1111/ane.12529) (PMID:26506904) (PMCID:PMC4738453)
|
Text
117861.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 146kB |
Abstract
Perampanel is approved for adjunctive therapy of focal epilepsy with or without secondarily generalized seizures in patients aged >12 years. This narrative review uses real-world and clinical trial data to elucidate perampanel's role in the clinic. Audit data show good tolerability with perampanel and higher freedom-from-seizure rates in elderly vs younger patients. When using perampanel in elderly patients, special attention should be given to comorbidities and co-medication to avoid potential interactions or adverse events. Slower titration is generally recommended, and seizure control should be reassessed at a dose of 4 mg before further dose increases. Perampanel efficacy is similar in adolescents and adults; however, somnolence, nasopharyngitis, and aggression are more frequent in adolescents vs the overall population. Individualized and slow-dose titration can minimize adverse events. Low serum concentrations of perampanel may occur in patients also receiving some enzyme-inducing anti-epileptic drugs; a perampanel dose increase may be required. Adverse events of importance with perampanel include dizziness; anger, aggression, and hostile behavior (particularly in adolescents); and falls (particularly in patients >65 years). An individualized approach to dosing, including slower up-titration and bedtime dosing, reduces dizziness risk. Other drugs may cause or aggravate dizziness; reducing concomitant drugs may be necessary when up-titrating perampanel. It would seem clinically appropriate to give due consideration to avoiding use in patients with a history of anger or hostile/aggressive behavior. The possibility of such behaviors should be discussed with patients before starting perampanel, with monitoring during up-titration. Slower up-titration of perampanel in older patients helps reduce fall risk.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Brodie, Professor Martin |
Authors: | Trinka, E., Steinhoff, B.J., Nikanorova, M., and Brodie, M.J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | Acta Neurologica Scandinavica |
Publisher: | Wiley |
ISSN: | 0001-6314 |
ISSN (Online): | 1600-0404 |
Published Online: | 28 October 2015 |
Copyright Holders: | Copyright © 2015 The Authors |
First Published: | First published in Acta Neurologica Scandinavica 133(3): 160-172 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record